In 2020, Anjana et al. found that PYCR1 protein levels were significantly higher than normal levels in breast cancer samples before treatment, decreased after treatment, but still significantly higher than normal levels, and high levels of PYCR1 in residual tumors were associated with short overall survival (24). This evidence concerns the gene PYCR1 and breast cancer.